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bstract
To optimally develop or adjust national contingency plans to respond to the next influenza pandemic, we developed a decision type
odel and estimated the total health burden and direct medical costs during the next possible influenza pandemic in the Netherlands on
he basis of health care burden during a regular epidemic. Using an arithmetic decision tree-type model we took into account population
haracteristics, varying influenza attack rates, health care consumption according to the Dutch health care model and all-cause mortality.
ctual direct medical cost estimates were based on the Dutch guidelines for pharmaco-economic evaluation. In the base-case scenario
ith no preventive measure available and an average influenza attack rate of 30%, 4,958,188 influenza infections, 1,552,687 GP consul-
ations, 83,515 hospitalizations and 173,396 deaths will take place in The Netherlands. The burden is highest in adults aged 20 to 64
ears. If minimizing the total mortality and sustaining highest net economic returns is the objective, this group needs to be targeted in
nterventions.
2006 Elsevier Ltd. All rights reserved.














Recent epidemics of highly pathogenic H5N1 avian
nfluenza with an estimated mortality rate exceeding 50%
n Asia [1], a report of probable person-to-person trans-
ission [2] and unusual clinical symptoms making differ-
ntial diagnosis a complicated task [3] warn the world of
he next influenza pandemic to come. Many Western coun-
ries have therefore been preparing themselves developing
nfluenza contingency plans. In The Netherlands, for exam-
le, a detailed planning of interventions during the different
andemic phases has been developed [4]. Only recently, the
utch Ministry of Health decided to stockpile 5 million doses
f the neuraminidase inhibitor oseltamivir®. A vaccine for
5N1 will not be available in the near future, and even if
vailable there will not be sufficient supply to cover Asian,
et alone, other countries. Importantly, the effectiveness of
∗ Corresponding author. Tel.: +31 30 2538214; fax: +31 30 2539028.
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oi:10.1016/j.vaccine.2006.05.065he neuraminidase inhibitors with regard to H5N1 influenza
is relatively unknown. The use of oseltamivir in five of the
en influenza H5N1 cases reported in Vietnam did not show
ny obvious effects, and mortality remained 80% [5]. Generic
ygienic measures aimed at reduction of transmission such
s reducing contact rates and social distance measures might
herefore be most important [6].
In any case, health care resource planning will be essential
o minimize social disruption in case of an influenza pan-
emic [7,8]. We therefore developed a decision type model
nd tried to estimate the total health care consumption in pri-
ary and secondary care, and associated mortality as well
s the total direct medical costs during the next possible
nfluenza pandemic in The Netherlands. The study was based
n estimates of health care consumption during a regular
nfluenza A (H3N2) epidemic [9]. Though much remains
ncertain in such predictions, these estimates might provide
ore insight into the expected health-economic burden to
ptimally develop or adjust national contingency plans to
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. Methods.1. Model parameters
The arithmetic decision tree-type model underlying the




Fig. 1. Mod2006) 6756–6760 6757
000, Microsoft) to take into account population characteris-
ics, varying influenza attack rates, health care consumption
ccording to the Dutch health care model and all-cause mor-
ality (see Fig. 1).
In accordance with previous mile-stone studies by Meltzer
7] and Van Genugten et al. [8] we subdivided the patient
el.
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Table 1





Outpatient visits age group 1-LR 5.8 1
Outpatient visits age group 1-HR 33.9 1
Outpatient visits age group 2-LR 7.5 1
Outpatient visits age group 2-HR 12.8 1
Outpatient visits age group 3-LR 12.1 1
Outpatient visits age group 3-HR 28.3 1
Hospitalizations age group 1-LR 0.113 2
Hospitalizations age group 1-HR 0.340 1
Hospitalizations age group 2-LR 0.333 2
Hospitalizations age group 2-HR 1.00 1
Hospitalizations age group 3-LR 2.3 1
Hospitalizations age group 3-HR 6.5 1
Deaths age group 1-LR 0.038 2
Deaths age group 1-HR 0.113 2
Deaths age group 2-LR 0.800 2
Deaths age group 2-HR 2.400 1
Deaths age group 3-LR 3.900 1
Deaths age group 3-HR 10.800 1
Abbreviations—1-LR: low-risk children (0–19 years); 1-HR: high-risk chil-
dren; 2-LR: low-risk adults (20–64 years); 2-HR: high-risk adults; 3-LR:
low-risk elderly (≥65 years); 3-HR: high-risk elderly.
















































































iRISMA data assuming similar distributions of deaths and hospitaliza-
ions as recorded in the elderly (ratio hospitalization:death = 1:3, ratio low
isk/high risk = 1:3).
opulation into children 0–19 years of age (N = 3,593,132
n 2004), adults 20–64 years of age (N = 10,379,439) and
lderly aged 65 years and older (N = 2,220,002). Further,
e subdivided these age groups according to the presence
r absence of risk-elevating medical conditions as men-
ioned in the influenza immunization guidelines by the Dutch
ealth Council (high-risk medical conditions in children:
%, adults: 12% and elderly: 40%).
The attack rates during pandemic influenza were estimated
o vary from 20% to 50% with a most likely average of 30%
10]. We used the average age-specific attack rates as esti-
ated by Glezen [11] on the basis of the three epidemics
n the 20th century (children: 38%, adults: 30% and elderly:
0%, all persons: 30%) and used multiplication factors to
stimate the outcomes based on the health outcomes during
he 1999–2000 influenza A (H3N2) epidemic with an average
nfluenza attack rate of 9%.
The probabilities of the complications and associated
ealth care use (33% of influenza cases needs health care)
n the model were based on data from the Dutch Preven-
ion of Influenza, Surveillance and Management (PRISMA)
tudy (Table 1) [9]. This influenza vaccine effectiveness case-
ontrol study was nested in a primary care cohort of approx-
mately 75,000 persons recommended for influenza vacci-
ation, and was conducted during the 1999–2000 influenza
(H3N2) epidemic. The major (possibly) influenza-related
omplications recorded were: pneumonia, acute otitis media,
cute lung disease, myocardial infarction, stroke, heart failure





ations was estimated for each subgroup. For example, of all
ow-risk children that consulted the GP, we estimated that
ost would have acute otitis media (77%) and the remainder
nfluenza or pneumonia (23%). In high-risk children, 29%
ould consult the GP for exacerbations of the asthma, 55%
or acute otitis media and 16% for influenza or pneumonia. In
ow- and high-risk adults and elderly, the most common rea-
on for encounter was acute respiratory disease (48%, 58%,
4% and 24%, respectively). In low- and high-risk adults and
lderly, sudden cardiac death was responsible for 12%, 14%,
8% and 23%, respectively, of all complications recorded in
rimary care. We observed no deaths in high-risk children
n the PRISMA study, but assumed similar ratio’s for hospi-
alization and deaths as in adults and elderly (3:1) to occur
uring a pandemic.
Initially a 1-year time horizon was used to predict short-
erm impact in terms of costs and burden of disease. We fur-
her adapted the model to be able to use the model to explore
he (long-term) survival impact of influenza. Each health state
r co-morbid condition is associated with a specific expected
ongevity. Based on national statistics and previously pub-
ished national predictions of future burden of disease, health
are resource use and expenditures, health state specific
long-term) estimates for the above outcomes were obtained.
or the calculation of the age- and co-morbidity-adjusted
ife expectancy we used complication-specific reduction fac-
ors. The age-adjusted life expectancy for children was 71
ears, 40 years for adults and 12 years for elderly persons
n average. A reduced life expectancy is used because of the
heoretical impact of co-morbidity of these complications on
ife expectancy. Reduction factors have been used to indicate
he reduction in survival after certain complications. Compli-
ations that result in reduced survival were COPD (reduction
actor 0.75), heart failure (0.50), myocardial infarction (0.50),
troke (0.75) and diabetes mellitus (0.75) [12].
Actual direct medical cost estimates were based on the
utch guidelines for pharmaco-economic evaluation [13] and
he Dutch medical economics guideline [14]. We estimated
he costs from a societal perspective and included average
osts for general practitioner visits, hospitalization and death.
uring an influenza-like illness, persons of all ages consult
heir general practitioner 1.9 times on average according to
uestionnaire data with an average of D 20.20 per consul-
ation. Since no other data are available that describe the
verage number of prescriptions per consultation in the three
ge groups, we conservatively assumed one prescription with
median net payment of D 9 as observed in the PRISMA
tudy. Data from the PRISMA study were used to estimate
edian costs associated with a hospitalization. The average
nit costs for hospitalizations were determined by calculat-
ng the weighted average unit costs for hospitalisation for the
ndications stroke, pneumonia, myocardial infarction, acute
ung disease, heart failure, stroke multiplied by the weighted
verage price per bed for general and academic hospitals
D 4252). Further, it was recorded that 35% of all hospital-
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unit cost D 2370); 83% of patients were brought to the hos-
ital by ambulance (unit cost D 306) and that 12% needed
dditional diagnostic research (unit cost D 33). The average
nit costs for hospitalization for the various indications plus
he additional components resulted in a total average unit
ost per hospitalization of D 5362. The costs of death were
etermined by the use of several health care components by
atients. Since there are no published data available on the
osts of death, we have tried to give an impression on the
omponents that have to be taken into account, i.e. general
ractitioner visit, consulting specialist, first aid, diagnostics,
tay at an intensive care unit and at a general ward and trans-
ort to the hospital with an ambulance (D 2391).
. Results
In the base-case scenario of a possible pandemic no pre-
entive measure is available and the average influenza attack
ate is assumed to be 30% with estimated group-specific
ttack rates in low-risk and high-risk children, adults and
lderly of 38%, 62%, 29%, 38%, 14% and 32%, respectively.
In all, 4,958,188 influenza infections, 1,552,687 GP con-
ultations, 83,515 hospitalizations and 173,396 deaths will
ake place in The Netherlands.
Absolute figures for GP consultations (965,798), hospi-
alizations (47,761) and deaths (132,860) are expected to
e highest in adults aged 20–64 years. Among children,
any GP consultations are to be expected (458,744) and
hese persons account for the lowest rates of hospitaliza-
ions and deaths (8440 and 2746, respectively). Among the
lderly, 128,135 GP consultations, 27,313 hospitalizations
nd 37,790 deaths would occur. With a time-horizon of 1 year,
he average numbers of life-years lost during a pandemic are
stimated at (173,396 × 40)/52 = 133,208. The remaining life
xpectancy analysis showed that 2,716,293 future life-years
re lost during a pandemic.
Overall, the total direct medical costs in one year are
stimated at D 843,679,580. The costs are higher for adults
D 569,002,321), than for elderly (D 214,127,301) and chil-
ren (D 60,549,958). In a total population of 16 million inhab-
tants, this means that from a direct medical cost perspective
ny preventive measure that has a real-life effectiveness of
reventing 50% of deaths during a pandemic (which equals
reduction of 1,358,147 life-years), would be cost-effective
t a maximum incremental cost of D 20,000/life-year gained
hen the costs of the measure per inhabitant would be D 1697
r lower.
. DiscussionOur data indicate substantial loss of life, health care con-
umption and economic losses during the next pandemic
n The Netherlands. Absolute hospitalization, mortality and
conomic cost figures are highest for the group aged between2006) 6756–6760 6759
0 and 64 years and considerable, though lowest, among chil-
ren.
The observation that mortality figures might be highest in
he under 65s during a pandemic is in agreement with recent
bservations by Simonsen et al. [15]. They found that the
roportion of total deaths among the under 65s was more
han 40% in the last three pandemics, and even 95% during
he Spanish pandemic of 1918–1919. Our observations are
lso in agreement with those from Meltzer who observed a
igh proportion of total number of deaths among the under
5s [7]. Van Genugten and colleagues used a scenario model
nd estimated more than 95% of deaths to occur among the
lderly [8]. However, in their model input for mortality figures
as estimated on the basis of excess figures for deaths due
o influenza and pneumonia. In younger persons, influenza
ay cause death through secondary complications that are
ot directly attributed to influenza and pneumonia, such as
ardiovascular complications, as observed in the PRISMA
tudy [9].
Setting priority for preventive measures in pandemic plan-
ing is guided by the objectives to be reached. Objectives
an range from minimizing the total mortality to sustain-
ng highest net economic returns. The data indicate that both
bjectives can be reached if the group aged between 20 and 64
ears is targeted in interventions. Our model does not take into
ccount virulence factors or transmission factors. However,
ost persons who suffered from avian influenza are currently
nder 65 years and transmission is highest among the group
ith highest contact rates, i.e. those under 65 years. More-
ver, if large numbers of working-age persons are affected,
s for example in many countries in which HIV is epidemic,
ocial disruption is inevitable.
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